Polarean Imaging AI Stock Analysis
Polarean Imaging (PLLWF) AI Stock Analysis
Polarean Imaging
(Other OTC:PLLWF)
No summary available
Polarean Imaging (PLLWF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $7.97M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- -2.72
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 29
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Polarean Imaging Business Overview & Revenue Model
Company Description
Polarean Imaging plc is a medical technology company specializing in drug-device combinations, catering to the medical imaging industry across the U.S., Canada, Germany, and the U.K. Its core business involves the creation and market introduction of...
Polarean Imaging Earnings Call Summary
The earnings call presented both achievements, such as increased sales quotes, a new NIH order, and international expansion efforts, and challenges, including disappointing first half revenue, market headwinds, and revised revenue guidance. While there are positive developments, significant challenges and setbacks in revenue and market conditions are impacting the company's performance.
Q2-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the investor presentation call for Polarean Imaging plc, CEO Christopher Von Jako and CFO Chuck Osborne discussed revised revenue guidance for 2025, now projected at $2.5 million to $3.5 million, down from the prior $5 million to $6 million. This revision follows a challenging first half with no new system sales, though a significant order from the NIH was announced. Despite market headwinds like NIH funding cuts and Medicaid reductions, leading to slowed capital purchases, consumable usage increased by 36% year-over-year, indicating strong engagement. Sales quotes surged by 650%, reaching over $21 million. The company anticipates returning to a $5 million to $6 million revenue trajectory in subsequent years as market conditions stabilize. Polarean is also focused on expanding its total addressable market, with pediatric approval broadening access to over 1 million potential patients and international advancements in Taiwan and Asia Pacific. The company remains financially disciplined, with $7.3 million in cash as of June 30, 2025, and is funded through Q2 2026.
Polarean Imaging Peers Comparison
Overall Rating
GB:IHC48.35Neutral
GB:SAR47Neutral
GB:CREO40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:IHC | 48Neutral | GBP 15.92M | -26.10 | -3.85% | ― | 0.88% | 94.67% |
| GB:SAR | 47Neutral | GBP 23.75M | -6.04 | -188.01% | ― | ― | 28.78% |
| GB:CREO | 40Underperform | GBP 46.60M | -2.23 | -38.29% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PLLWF | Polarean Imaging Plc | 0.01 | 0.00 | 0.00% | |
| GB:CREO | Creo Medical | 10.13 | -0.13 | -1.22% | |
| GB:IHC | Inspiration Healthcare | 17.75 | -2.50 | -12.35% | |
| GB:SAR | Sareum Holdings | 14.50 | 0.75 | 5.45% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.